EUVIMED · CrossrefJournal
Antibody Therapeutics
ISSN 2516-4236 · Oxford University Press (OUP)
Latest articles
Potent Antitumor Efficacy of a Novel ALPPL2/ALPP-Targeting Antibody-Drug Conjugate in Preclinical Models
Engineering a novel asymmetric head-to-tail (HtT) 1+1 and 2+1 T cell bispecific antibody (TCB) platform with superior T cell killing compared to 1+1 bispecific IgG antibodies
Hetero-hexamerization as a means to improve broadly neutralizing antibody activity against HIV-1
The barrier effect of high-affinity IgM neutralizing antibodies provides enhanced blockage against rabies virus transport and infection
PPBind-3D/1D: protein–protein binding affinity prediction for structural and sequence data
Experimentally anchored, MHC-agnostic prediction of immunogenicity and cytokine release
Beyond affinity: AI-supported developability assessment and multi-objective optimization in antibody development
Ultrahigh-DAR antibody–drug conjugates: advancing the next generation of targeted therapy
Dual-component CAR T cell therapy: targeting BCMA with convertible CAR and MicAbodies
Generation and characterization of a CEACAM5 × CDH17 × CD3 tri-specific T-cell engager for colorectal cancer therapy
Profiling the efficacy of CR1 monoclonal antibody series against New World Arenaviruses
Developability improvement of an MMP-9 inhibitory mAb by CDR-H3 hydrophobic residue substitution
Mass photometry reveals stoichiometry and binding dynamics of bispecific tetravalent anti-VEGF–PD-1 antibody ivonescimab
Novel ADC and γδ T cell engager targeting CDH17 for the therapy of gastrointestinal cancers
TROP2 antibody–drug conjugate: unique epitope engagement drives differentiated efficacy
Generative AI–driven de novo design of high-affinity, epitope-specific antibodies targeting the CD93–IGFBP7 axis for cancer immunotherapy
The evolving landscape of enzymatic technologies for precision synthesis of antibody–drug conjugates
Cytotoxic activity and safety characterization of IMV-M™, a MUC16 × DR5 bispecific antibody
Antibody-oligonucleotide conjugates: an emerging modality for precision RNA therapeutics
On-column thiol protection strategy to control charge and stability of ThiomAb
Integrating fab phage and yeast display through seamless transfer of paired heavy- and light-chain libraries for efficient antibody discovery
Subcutaneous administration of antibody–drug conjugates: current challenges, emerging opportunities, and future perspectives
From T cell engagers to next-generation immune cell engagers for cancer immunotherapy
Anti-ANGPTL3 antibody and IL-22 fusion protein mitigate nephrotic syndrome via mitochondrial protection, anti-apoptosis, and autophagy suppression
Delivery devices and container closure systems for co-formulated and co-administered biologics
Fully human antagonistic antibodies targeting FPR2 through dual extracellular-loop engagement for gastric cancer therapy
Conformational epitope engagement by anti-MSLN ADC RC88 confers resistance to soluble mesothelin
Challenges and solutions for upstream processing of complex biologics
Thanks to Our Reviewers in 2023-2025
Systematic functional screening of immunoreceptor tyrosine-based inhibitory motif domains identifies potent inhibitory modules for chimeric antigen receptor-T
EUVIMED